Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions
- 1 June 2003
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (9) , 1351-1361
- https://doi.org/10.1097/00002030-200306130-00009
Abstract
Objective: To monitor the disappearance of resistance-associated mutations and reappearance of wild-type (WT) virus during structured treatment interruptions (STI) using DNA sequencing and line probe assay. Methods: Eleven HIV-1-infected patients participating in the MUTAVIR study undergoing a 3-month STI after multi-HAART failure were monitored biweekly. Genotypes were assessed by sequencing and VERSANT® HIV-1 Resistance Assays (LiPA). Results: At treatment interruption, 54 mutations in total were identified with both methods among the patients. LiPA provided a result for 93.3% of the codons at baseline. For 37 mutations, a complete reversion of mutant to WT was observed with one of the two methods. Among these, LiPA detected mutations in 23 codons for 7 to 52 days longer, in 10 codons for the same period, and in four codons for a shorter time than sequencing. Similarly, LiPA detected 35 WT codons 8 to 86 days earlier, and 15 at the same time point as sequencing. A sharp reduction in the number of mutations was observed at the time of viral load increase in five of the 11 patients. Taking only the codons detected by LiPA into consideration, two patients showed a complete reversion to WT according to both genotyping assays at the end of the STI period. Conclusions: The determination of the timepoint at which a virus population of an HIV-1 patient undergoing STI reverts to WT is dependent on the assay used. The viral load increase in most patients is compatible with the outgrowth of virus with fewer or no mutations.Keywords
This publication has 16 references indexed in Scilit:
- Structured treatment interruptions for the management of HIV infection.JAMA, 2001
- Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral TherapyJournal of Virology, 2001
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Structured treatment interruptions in antiretroviral management of HIV-1Current Opinion in Infectious Diseases, 2001
- Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugsAIDS, 2000
- Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotypeAIDS, 1999
- Phenotypic Assays and Sequencing Are Less Sensitive Than Point Mutation Assays for Detection of Resistance in Mixed HIV-1 Genotypic PopulationsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and TherapyScience, 1995